Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 6
Monitoring Adverse Events Following CAR T-Cell Therapy
A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.
- Dr. Usmani: What is your protocol for monitoring and grading of neurotoxicity, cytokine release syndrome (CRS), and other acute toxicities immediately following CAR-T cell infusion?
- Are there any subgroups of patients you have found to be at particularly high risk for delayed neurotoxicity requiring extended monitoring?
- What are your institutional guidelines around administering steroids, anti-seizure medications, or other treatments for severe neurotoxicity?
Recent Videos
Related Content
